Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) is now available.
Jiangsu Recbio Technology has announced a leadership reshuffle, with founder-executive Dr. Liu Yong stepping down as chairman of the board and head of the nomination committee to focus on other commitments while remaining as an executive director and general manager overseeing the company’s production, operations and overall management. The board has elected veteran pharmaceutical executive Xu Haoyu, chairman and president of Yangtze River Pharmaceutical Group and a prominent industry figure in China, as the new non-executive chairman; Xu and his family collectively hold significant indirect stakes in Recbio through multiple shareholding vehicles, a move that further tightens strategic ties with Yangtze River Pharmaceutical and may influence the company’s governance structure, strategic direction and access to industry resources.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a Chinese biopharmaceutical company listed in Hong Kong that focuses on vaccine and related biotech innovation, operating within the broader healthcare and life sciences industry and serving both domestic and international markets through its H share structure.
Average Trading Volume: 48,308
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.43B
See more insights into 2179 stock on TipRanks’ Stock Analysis page.